Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
You may also be interested in...
Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.
Acting Administrator Andy Slavitt explains CMS is in information-gathering mode as it considers ways of addressing accelerating drug costs in Medicare and Medicaid.
The idea raised by health policy experts that high-cost drugs could be paid for in installments over a number of years doesn't appeal to insurance executives at recent conference.